MASLD Cirrhosis Before 50: Diabetes, Genetics—and a Blind Spot in Current Screening: CGH | September 2026

What Did the Study Find?

Investigators analyzed approximately 2,400 adults with biopsy-confirmed MASLD to characterize cirrhosis developing before age 50.

About 25% of cirrhosis cases occurred before age 50.

Early-onset cirrhosis showed a distinct risk profile driven particularly by type 2 diabetes and genetic susceptibility.

Obesity and other metabolic factors further contributed to risk.

Importantly, nearly one-third of patients with early-onset cirrhosis would not have triggered further evaluation using standard fibrosis-screening thresholds.

This highlights a potential limitation of commonly used fibrosis scores that incorporate age, which can underestimate risk in younger adults.

Why Does It Matter?

MASLD cirrhosis can remain clinically silent until decompensation or liver cancer develops. Age-dependent screening strategies may provide false reassurance in younger metabolically high-risk patients.

GastroAGI Takeaway

Young age should not reassure us when metabolic and genetic risk is high. In younger adults with MASLD—particularly those with type 2 diabetes, obesity or strong genetic/familial susceptibility—a low age-influenced fibrosis score may warrant cautious interpretation and consideration of additional non-invasive fibrosis assessment. Earlier recognition of cirrhosis also ensures timely HCC surveillance and cirrhosis-specific care.